4-(叔丁基甲酰氨)苯基硼酸 | 850568-14-8

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(叔丁基甲酰氨)苯基硼酸
• 中文别名: 4-(叔丁基氨基羰基)苯硼酸
• 英文名称: 4-(tert-butylcarbamoyl)phenylboronic acid
• 英文别名: [4-(tert-butylaminocarbonyl)phenyl]boronic acid；(4-(tert-Butylcarbamoyl)phenyl)boronic acid；[4-(tert-butylcarbamoyl)phenyl]boronic acid
• CAS: 850568-14-8
• 化学式: C₁₁H₁₆BNO₃
• mdl: MFCD03788413
• 分子量: 221.064
• InChiKey: JAIIZPWLCVMPFA-UHFFFAOYSA-N

物化性质

• 熔点：
  230-246°C

计算性质

• 辛醇/水分配系数(LogP)：
  1.37
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-(tert-Butylaminocarbonyl)phenylboronic acid
Product Name:
Synonyms: N-t-Butyl 4-boronobenzamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-(tert-Butylaminocarbonyl)phenylboronic acid
Ingredient name:
CAS number: 850568-14-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H16BNO3
Molecular weight: 221.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(叔丁基甲酰氨)苯基硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 palladium 10% on activated carbon 氯化亚砜 、 四丁基氟化铵 、 氢气 、 sodium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 为溶剂， 20.0~100.0 ℃ 、344.75 kPa 条件下， 反应 24.0h， 生成 4-[2-cyclopentyl-1-(1H-pyrrolo[2,3-b]pyridin-2-yl)-ethyl]-benzonitrile
  参考文献：
  名称：

  AZAINDOLE GLUCOKINASE ACTIVATORS

  摘要：

  提供的化合物为公式(I)： 以及其中可接受的药用盐，其中取代基如说明书所述。这些化合物以及包含它们的药物组合物，可用于治疗代谢性疾病和障碍，例如，2型糖尿病。

  公开号：

  US20110144105A1
• 作为产物：
  描述：

  4-羧基苯硼酸 、 叔丁胺 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以70.7%的产率得到4-(叔丁基甲酰氨)苯基硼酸
  参考文献：
  名称：

  AZAINDOLE GLUCOKINASE ACTIVATORS

  摘要：

  提供的化合物为公式(I)： 以及其中可接受的药用盐，其中取代基如说明书所述。这些化合物以及包含它们的药物组合物，可用于治疗代谢性疾病和障碍，例如，2型糖尿病。

  公开号：

  US20110144105A1

文献信息

• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014135495A1

  公开（公告）日：2014-09-12

  The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

  本发明公开了化合物的结构式I：其中结构式I中的变量如本文所述。还公开了含有这些化合物的药物组合物，以及使用结构式I中的化合物预防或治疗HCV感染的方法。
• Arynes and Their Precursors from Arylboronic Acids via Catalytic C–H Silylation
  作者：Karthik Devaraj、Fredric J. L. Ingner、Carina Sollert、Paul J. Gates、Andreas Orthaber、Lukasz T. Pilarski

  DOI：10.1021/acs.joc.9b00221

  日期：2019.5.3

  A new, operationally simple approach is presented to access arynes and their fluoride-activated precursors based on Ru-catalyzed C–H silylation of arylboronates. Chromatographic purification may be deferred until after aryne capture, rendering the arylboronates de facto precursors. Access to various new arynes and their derivatives is demonstrated, including, for the first time, those based on a 2

  提出了一种新的，操作简单的方法，该方法基于Ru催化的芳基硼酸酯的C–H甲硅烷基化来获得芳烃及其氟化物活化的前体。色谱纯化可推迟至芳烃捕获后进行，使芳基硼酸酯成为事实上的前体。展示了使用各种新的芳烃及其衍生物的方法，包括首次使用基于2,3-咔唑基和2,3-芴炔核的芳烃，这些化合物为与材料化学相关的图案的新颖衍生化铺平了道路。
• Azaindole glucokinase activators
  申请人：Hoffmann-La Roche Inc.

  公开号：US08222416B2

  公开（公告）日：2012-07-17

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

  本文提供的是公式(I)的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物和含有它们的药物组合物，可用于治疗代谢性疾病和紊乱，例如2型糖尿病。
• ANTIVIRAL COMPOUNDS
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20160000760A1

  公开（公告）日：2016-01-07

  The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

  本发明公开了I式化合物：其中I式中的变量如本文所述。还公开了包含这种化合物的药物组合物，以及使用I式化合物在预防或治疗HCV感染方面的方法。
• Arylphthalazines: Identification of a new phthalazine chemotype as inhibitors of VEGFR kinase
  作者：Evgueni L. Piatnitski、Matthew A.J. Duncton、Alexander S. Kiselyov、Reeti Katoch-Rouse、Dan Sherman、Daniel L. Milligan、Chris Balagtas、Wai C. Wong、Joel Kawakami、Jacqueline F. Doody

  DOI：10.1016/j.bmcl.2005.07.064

  日期：2005.11

  A novel class of 4-arylamino-phthalazin-1-yl-benzamides is described as inhibitors of vascular endothelial growth factor receptor II (VEGFR-2). Several compounds display potent VEGFR-2 inhibitory activity with an IC50 as low as 0.078 mu M in an HTRF enzymatic assay. These compounds are relatively selective against a small kinase panel. (c) 2005 Elsevier Ltd. All rights reserved.